Azenta, Inc.
AZTA
Positions held
Your positionsAZTA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Azenta, Inc. operates in the growing medical instruments and supplies industry, which is expected to expand due to increasing healthcare demands and technological advancements.
- Revenue increased by 11% compared to the prior quarter, reaching $161 million.
- Gross margin improved to 44.9%, up from 42.8% in the previous quarter.
- Despite growth potential, Azenta has a high forward P/E ratio of 71.22, indicating that the stock may be overvalued relative to its earnings.
- The company reported a net income loss of $160.798 million in Q1 2026, reflecting ongoing profitability challenges.
- Operating margin remains negative at -2.3%, indicating that the company is still struggling to achieve operational efficiency.
Fundamentals
| Market cap | $1.58B | Enterprise value | $1.31B | Trailing P/E | — | Forward P/E | 65.16 |
| PEG | 0.53 | Price / book | 1.04 | Beta | 1.52 | Dividend yield | 0.00% |
| Revenue growth | 12.0% | Earnings growth | — | Gross margin | 44.0% | Operating margin | -2.3% |
| Profit margin | -20.0% | ROE | -7.0% | ROA | -0.7% | Debt / equity | 0.04 |
| Current ratio | 2.50 | Free cash flow | $63.37M | Analyst recommendation | buy | Mean target | $37.00 |
| 52w high | $46.41 | 52w low | $15.93 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $161M | $145M | $149M | $159M | $144M | — |
| Op margin | -2.3% | -10.6% | -4.1% | 1.1% | -0.8% | — |
| Net income | $2.5M | -$161M | -$15.4M | $50.8M | -$48.0M | — |
| Gross margin | 44.9% | 42.8% | 42.9% | 42.8% | 46.2% | — |
| Gross profit | $72.4M | $62.0M | $63.7M | $68.0M | $66.4M | — |
| Operating income | -$3.7M | -$15.3M | -$6.1M | $1.8M | -$1.1M | — |
- Revenue +11% vs prior quarter ($161M vs $145M).
- Gross margin 44.9% (was 42.8% prior quarter).
- Operating margin expanded to -2.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $594M | $573M | $551M | $555M |
| Op margin | -3.6% | -7.0% | -10.3% | -4.2% |
| Net income | -$55.8M | -$165M | -$14.6M | $2.1B |
| Gross margin | 45.5% | 44.4% | 43.4% | 46.0% |
| Gross profit | $270M | $255M | $239M | $256M |
| Operating income | -$21.7M | -$39.9M | -$56.7M | -$23.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-14 · Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)
2026-09-10 · Brooks Automation Files Confidentially for IPO
2026-09-04 · Azenta Receives Early Repayment of $35 Million Vendor Loan
2026-09-04 · Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems
2026-09-01 · 3 Healthcare Stocks We Keep Off Our Radar
2026-08-25 · Stocks making big moves yesterday: Funko, Hims & Hers Health, Azenta, Strategy, and RUM Group
2026-08-24 · Why Azenta (AZTA) Stock Is Down Today
2026-08-24 · Top Midday Decliners
2026-08-24 · Azenta Names Board Member Martin Madaus as Interim CEO
2026-08-24 · AZENTA ANNOUNCES LEADERSHIP TRANSITION
2026-08-19 · 1 Momentum Stock for Long-Term Investors and 2 We Find Risky
2026-08-13 · The 5 Most Interesting Analyst Questions From Azenta’s Q2 Earnings Call
Price (daily)
Full chart · RSI · MACD · patterns